Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment

NCT00242736 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00242736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2005
Completion date
January 31, 2006
Enrollment
350
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

gerd